Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.
Glivec Research Today
Home
View Latest Issue
Information About Glivec
Books on Glivec
Advertising in Research Today
View Other Research Today Publications
© 2004-2008 Glivec Research Today. All Rights Reserved.
Glivec Research Today Archive:
Volume 1 (2004) Issue 1 (October) Issue 2 (November) Issue 3 (December)
Volume 2 (2005) Issue 1 (January) Issue 2 (February) Issue 3 (March) Issue 4 (April) Issue 5 (May) Issue 6 (June) Issue 7 (July) Issue 8 (August) Issue 9 (September) Issue 10 (October) Issue 11 (November) Issue 12 (December)
Volume 3 (2006) Issue 1 (January) Issue 2 (February) Issue 3 (March) Issue 4 (April) Issue 5 (May) Issue 6 (June) Issue 7 (July) Issue 8 (August) Issue 9 (September) Issue 10 (October) Issue 11 (November) Issue 12 (December)
Volume 4 (2007) Issue 1 (January) Issue 2 (February) Issue 3 (March) Issue 4 (April) Issue 5 (May) Issue 6 (June) Issue 7 (July) Issue 8 (August) Issue 9 (September) Issue 10 (October) Issue 11 (November) Issue 12 (December)
Volume 5 (2008) Issue 1 (January) Issue 2 (February) Issue 3 (March) Issue 4 (April) Issue 5 (May) Issue 6 (June) Issue 7 (July) Issue 8 (August)
![Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated ... Toxicology and Environmental Mutagenesis]](http://glivec.researchtoday.net/images/glivec-B000RR82FG.jpg "Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated ... Toxicology and Environmental Mutagenesis]")